Investigating race and gender in age at onset of hidradenitis suppurativa

Morss, Peyton; Porter, Martina L.; Savage, Kevin T.; Santillan, Monica Rosales; Giannotti, Nicole; Kimball, Alexa B.

doi:10.1111/jdv.16095

Cited by 9 publications

(13 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, the average age of HS onset in patients who first developed Pso is 36.6 years, which is significantly later. Similarly, the mean age of on-set of Pso, according to a large Italian analysis, is around 33 years [34]. In our investigation, the mean age in the entire cohort was 29.5 years, but in patients who first developed Pso, it was significantly earlier with 24.3 years.…”

Section: Prevalence and Onset Of Diseasesupporting

confidence: 39%

Coprevalence of Hidradenitis Suppurativa and Psoriasis: Detailed Demographic, Disease Severity and Comorbidity Pattern

et al. 2020

View full text Add to dashboard Cite

Background and Objectives: Hidradenitis suppurativa (HS) and plaque psoriasis (Pso) are supposed to have a coprevalence. However, data showing a more detailed description of patients with both diseases are rare. In this study, we characterized patients with both skin diseases in terms of onset, disease course, severity, concomitant diseases and therapeutical management. Patients and Methods: Data from 28 patients with a confirmed codiagnosis of HS and Pso from 2 university hospitals presented between 2015 and 2019 were evaluated retrospectively. For further characterization, patients were divided into different cohorts depending on whether HS or Pso was diagnosed as the first disease. Results: The average age of patients with a coprevalence of both diseases was 44.4 years with a female/male ratio of 1:1.15. Fifteen patients were diagnosed first with HS at an average age of 22.8 years, 13 patients first showed symptoms of Pso at a mean age of 21.7 years. The average time to the onset of the corresponding second disease was 14.3 years. Patients with HS as first disease showed a significantly severer form of HS compared to patients with a first diagnosis of Pso (mean highest International Hidradenitis Suppurativa Severity Score System: 23.5 vs. 8.2; p = 0.02). Severity of psoriatic disease in patients with HS at first diagnosis was numerically lower but not significant compared to the cohort with Pso at first diagnosis (mean highest Psoriasis Area and Severity Index: 7.8 vs. 13.2; p = 0.299). The most frequent comorbidity in all patients was obesity (64.3%; mean body mass index: 32.2) followed by psychiatric complaints (25%) and psoriatic arthritis (21.4%). Adalimumab was the most commonly used drug that had a positive effect on both diseases, HS and Pso. Conclusions: In patients with a coprevalence of HS and Pso, the disease which occurs first appears to take a severer course, with an increased risk of development of obesity and psychiatric comorbidity in both cohorts.

show abstract

Section: Prevalence and Onset Of Diseasesupporting

confidence: 39%

Coprevalence of Hidradenitis Suppurativa and Psoriasis: Detailed Demographic, Disease Severity and Comorbidity Pattern

et al. 2020

View full text Add to dashboard Cite

show abstract

“…50 Data regarding HS severity by race conflict with one study suggesting that African American patients may have earlier disease onset and are more likely to present with advanced disease compared to Whites. 57,58 Genetic studies have identified several γ-secretase mutations linked to HS pathogenesis. Although these mutations were initially reported in Han Chinese families, the same mutations have subsequently been detected in HS patients worldwide.…”

Section: R Acial Backg Round and H Smentioning

confidence: 99%

“…Gluteal distribution has been observed more frequently in Asian than in European and American HS cohorts, possibly related to male predominance in the Asian cohorts 50 . Data regarding HS severity by race conflict with one study suggesting that African American patients may have earlier disease onset and are more likely to present with advanced disease compared to Whites 57,58 …”

Section: Racial Background and Hsmentioning

confidence: 99%

What causes hidradenitis suppurativa ?—15 years after

Zouboulis

Benhadou

Byrd

et al. 2020

Experimental Dermatology

132

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…Furthermore, country-specific and ethnic-specific differences may explain different clinical and comorbidity profiles of pediatric HS across observational studies and disease registries. 33,34 Clinical management of pediatric HS is poorly described in the literature and generally follows the principles and clinical practice guidelines of adult-onset HS. 6,35 In our cohort, medical treatment was mostly based on the association of clindamycin -or zinc sulphate salts based regimens and topicals.…”

Section: Discussionmentioning

confidence: 99%

Pediatric Hidradenitis Suppurativa: A Cross-Sectional Study on Clinical Features and Treatment Approaches

et al. 2021

View full text Add to dashboard Cite

Background Hidradenitis suppurativa is uncommon in patients of pediatric age, and differentiation with adult-onset disease is controversial. Treatment of pediatric hidradenitis suppurativa is scarcely standardized, and specific guidelines are lacking. Objective We report the clinical features, relevant risk-factors, comorbidity profile, and treatment patterns of a hospital-based cohort of pediatric hidradenitis suppurativa Methods In a cross-sectional study data on patients’ demographics, disease-specific characteristics, early/pre-pubertal onset of disease, comorbidities, and treatment management were retrieved. Reference population data and clinical data from the national hidradenitis suppurativa disease registry were used for comparison. Results From a database of 870 patients with hidradenitis, 71 (15 males and 56 females) patients aged <18 years (mean age: 15.3 years; range 8-17 years), with mild (Hurley I, 45.1%) and moderate-severe disease (Hurley II-III, 54.9%), were retrieved. Smoking (23.9%) and overweight/obese frequencies (59.2%) were higher than reference population standards. Patient’s older age at baseline (OR 1.43, 95% CI: 1.01 to 2.02) and higher BMI (OR 1.26, 95% CI: 1.07–1.48) were the only factors associated with moderate-severe disease. Family history and early/pre-pubertal onset of disease were not associated with severity or extent of disease. Sebaceous-follicular comorbid conditions were associated with cigarette smoking ( P = .002). Among 81 treatment courses, clindamycin-based and zinc-sulphate-based combination regimens were most frequently used (59.3%). Female preponderance, family history of disease and extensive involvement were significantly different from the general hidradenitis suppurativa population. Conclusions Pediatric hidradenitis suppurativa presents a clinical spectrum comparable to adult-onset disease. Increased preventive measures should target obesity and smoking in this population.

show abstract

Investigating race and gender in age at onset of hidradenitis suppurativa

Cited by 9 publications

References 7 publications

Coprevalence of Hidradenitis Suppurativa and Psoriasis: Detailed Demographic, Disease Severity and Comorbidity Pattern

Coprevalence of Hidradenitis Suppurativa and Psoriasis: Detailed Demographic, Disease Severity and Comorbidity Pattern

What causes hidradenitis suppurativa ?—15 years after

Pediatric Hidradenitis Suppurativa: A Cross-Sectional Study on Clinical Features and Treatment Approaches

Contact Info

Product

Resources

About